The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity

نویسندگان

  • Paul Kotwinski
  • Gillian Smith
  • Julie Sanders
  • Louise Ma
  • Jackie Cooper
  • Michael Thomas
  • Michael (Monty) G Mythen
  • Alison Jones
  • Hugh E Montgomery
  • Dudley J Pennell
چکیده

The breast cancer, early disease: toxicity from therapy with epirubicin regimens cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity Paul Kotwinski, Gillian Smith, Julie Sanders, Louise Ma, Jackie Cooper, Michael Thomas, Michael (Monty) G Mythen, Alison Jones, Hugh E Montgomery, Dudley J Pennell

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

CMR shows that anthracycline cardiotoxicity is common in women treated for early breast cancer and associated with undiagnosed hypertension; but cannot be reliably detected using late-gadolinium enhancement imaging

Background A growing number of patients with cancer are at risk from chronic anthracycline cardiotoxicity (cAC) as a result of improving cancer prognosis. Although susceptibility is cumulative dose-related, it is also idiosyncratic. Furthermore, at present there is no way to reliably identify those at risk. The common practice of serially measuring LV ejection fraction (LVEF) only identifies ca...

متن کامل

Anthracycline cardiotoxicity after breast cancer treatment.

Anthracyclines are among the most active agents for the treatment of breast cancer; their use in combination regimens improves both disease-free and overall survival in patients with breast cancer. Unfortunately, the clinical utility of anthracycline use is limited by a cumulative dose-dependent cardiac toxicity resulting in congestive heart failure. As methods for detecting and treating breast...

متن کامل

Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial

Anthracycline-induced cardiotoxicity influences treatment selection and may negatively affect clinical outcomes in lymphoma patients. While epirubicin induced cardiotoxicity less often than the same dose of doxorubicin in breast cancer, higher doses of epirubicin are required in lymphoma regimens for equivalent efficacy. Whether a higher dosage of epirubicin also induces cardiotoxicity less oft...

متن کامل

Rapid Health Technology Assessment of Oncotype DX in Patients with Early-Stage Breast Cancer

Introduction: Breast cancer is the most common cancer in women. Patients are treated with chemotherapy initially, and if not chemically treated, the risk of recurrence of the disease increases yearly. Therefore, methods for identifying patients for whom chemotherapy would be most beneficial are very important. The Oncotype DX test is a prognostic assay that predicts the likelihood of breast can...

متن کامل

Evaluation of Anthracycline Effects on NT-ProBNP Plasma Level in Children with Malignancy

Background: NT-proBNP is a marker that is released from ventricles in response to pressure and volume overload. Raised plasma level of NT-proBNP is seen in ventricular dysfunction, ventricular muscular mass reduction or ventricular ischemia. Anthracyclines are widely used in treatment of pediatric cancer but their use is associated with cardiotoxicity which increases mortality and morbidity. We...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 15  شماره 

صفحات  -

تاریخ انتشار 2013